Nexalin Technology, Inc. (NXL) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
1776 Yorktown
Houston, TX 77056
United States of America (the)
Phone
713 660 1100
Website
Sector
Healthcare
Industry
Medical - Devices
Employees
6
First IPO Date
September 16, 2022
| Name | Title | Pay | Year Born |
| Mark White | President, Chief Executive Officer & Director | 598,000 | 1962 |
| David Owens | Chief Medical Officer, Member of Scientific Advisory Board & Director | 50,600 | 1962 |
| Carolyn Shelton | Executive Vice President of Clinical, Quality & Regulatory Affairs | 340,000 | 1963 |
| John Patrick Claude | Co-Founder and Director of Engineering & Development | 0 | N/A |
| Justin Van Fleet | Chief Financial Officer | 0 | 1981 |
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.